Veterinary Medicines

Doxycare Flavour 200 mg Tablets for Cats and Dogs

Authorised
  • Doxycycline hyclate
Download as PDF

Product identification

Medicine name:
Doxycare Flavour 200 mg Tablets for Cats and Dogs
Doxycare Vet. 200 mg tabletter
Active substance:
  • Doxycycline hyclate
Target species:
  • Dog
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Doxycycline hyclate
    239.40
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01AA02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Denmark
Available in:
  • Denmark
Package description:
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 90 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 100 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 250 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 10 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 20 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 30 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 40 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 50 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 60 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 70 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 80 tablets.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Ecuphar
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
Responsible authority:
  • Danish Medicines Agency
Authorisation number:
  • 61155
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0645/002
Concerned member states:
  • Austria
  • Belgium
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 6/04/2025
Download
Danish (, TABLETTER 40 MG OG 200 MG)
Published on: 29/06/2023
Download

Combined File of all Documents

English (PDF)
Published on: 6/04/2025
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."